Form D · Biotechnology

Senti Biosciences Holdings, Inc.

South San Francisco, CA · CIK 0001854270

Offering snapshot reported Jun 4, 2026 · SEC filing

Reported sold
$10M
Offering amount: $40M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
May 20, 2026
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 4, 2026Initial$10,000,000No comparison1SEC filing
Dec 19, 2024Initial$37,604,250No comparison15SEC filing

Offering details

Securities
Debt, Other
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-586137
Senti Holdings, Inc. sold notes convertible into its Common Stock or exchangeable into shares of Senti Biosciences Holdings, Inc. Common Stock and guaranteed by Senti Biosciences Holdings, Inc. and certain of its subsidiaries.
Guarantee

Source: Form D, filed Jun 4, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Bryan Baum Director
James J. Collins Director
Brenda Cooperstone Director
Jay Cross Executive
Feng Hsiung Director
Yvonne Li Executive
Timothy Lu Director, Executive
Edward Mathers Director
Kanya Rajangam Executive
Frances D. Schulz Director
Fran Schulz Director
Donald Tang Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
2 Corporate Drive, First Floor
South San Francisco, CA, 94080